My colleagues at FTI Consulting, Mark Van Ert and Krunal Patel, have outlined some of the new quality measures that will be included in the 2025 CMS Star Ratings, which are crucial for evaluating Medicare Advantage plans. The CMS payments to MA plans are set to increase by $16 billion in 2025. The CMS ratings cycle consists of a four-year process, with specific measures being collected and evaluated each year.
The new measures for 2025 include evaluating the simultaneous use of opioids and benzodiazepines, the use of multiple anticholinergic medications in older adults, kidney health for diabetic patients, and assessing both physical and mental health outcomes. For more information on the technical specifications of all CMS Star Rating quality measures, click here. To learn more about the new CMS Star Ratings Measures for 2025, visit the article on Healthcare Economist.
